MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company developing immunotherapies for inflammatory diseases using Nanobody technology. Its pipeline is built around next-level immunotherapies that target relevant immune pathways, with programmes directed at conditions such as hidradenitis suppurativa and inflammatory skin and joint diseases. The work sits at the intersection of immunology, dermatology and rheumatology, in areas the company identifies as having significant unmet medical need.

The company is publicly listed on NASDAQ under the ticker MLTX. Its technical scope spans Nanobody technology, immunotherapy, clinical-stage drug development, immunology and data and analytics. Alongside its clinical work, it uses analysis of patient and prescriber patterns and market coverage to inform commercialization and go-to-market decision-making.

MoonLake publishes clinical trial updates and maintains an investor relations function as part of its communications. The stated focus of its development effort is on improving treatment outcomes for patients with immunologic conditions.